Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial

被引：0

作者：

Jiang, Y-F. ^{[1
]}

Bei, W-X. ^{[1
]}

Wang, L. ^{[2
]}

Xu, C. ^{[2
]}

Lu, N. ^{[3
]}

Liang, H. ^{[4
]}

Ke, L-R. ^{[3
]}

Ye, Y-F. ^{[5
]}

Fang, T. ^{[1
]}

He, S. ^{[6
]}

Dong, S-H. ^{[1
]}

Liu, Q. ^{[1
]}

Zhang, C. ^{[1
]}

Xia, W. ^{[1
]}

Zhao, C. ^{[1
]}

Xie, C. ^{[7
]}

Liu, G. ^{[8
]}

Xiang, Y-Q. ^{[1
]}

机构：

[1] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ Canc Ctr, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China

[3] Sun Yat Sen Univ Canc Ctr, Dept Radiol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China

[4] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China

[5] Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China

[6] Sun Yat Sen Univ, Radiat Oncol, Guang Zhou, Peoples R China

[7] NCI, Thorac & GI Malignancies Branch, Bethesda, MD USA

[8] Sun Yat Sen Univ, Radiotherapy Dept, Guangzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.954

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

893P

引用

页码：S633 / S634

页数：2

共 50 条

[1] Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial
Jiang, Yaofei
Bei, Weixin
Wang, Lin
Lu, Nian
Xu, Cheng
Liang, Hu
Ke, Liangru
Ye, Yanfang
He, Shuiqing
Dong, Shuhui
Liu, Qin
Zhang, Chuanrun
Wang, Xuguang
Xia, Weixiong
Zhao, Chong
Huang, Ying
Xiang, Yanqun
Liu, Guoying
BMC MEDICINE, 2025, 23 (01):
[2] Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.
Wahafu, Wasilijiang
Wei, Shuqing
Qiao, Xiaoyuan
Zhang, Xi
Wang, Mingshuai
Han, Sujun
Cui, Yu
Han, Xuebing
Pang, Dongzi
Bai, Hongsong
Hu, Linjun
Li, Zhibin
Wang, Xin
Fan, Yuzhu
Xing, Nianzeng
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial
Wu, Xiaohua
Ji, Jiafu
Lou, Hanmei
Li, Yunxia
Feng, Mei
Xu, Nong
Li, Yuzhi
Wang, Jing
Huang, Yi
Lou, Ge
An, Ruifang
Li, Changzheng
Zhou, Qi
Huang, Xin
Zhao, Enfeng
Liu, Tianshu
Fan, Qingxia
Li, Guiling
Li, Baiyong
Xia, Yu
GYNECOLOGIC ONCOLOGY, 2022, 166 : S47 - S48
[4] Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study
Chen, Xiaozhong
Wang, Wei
Zou, Qingfeng
Zhu, Xiaodong
Lin, Qin
Jiang, Yi
Sun, Yan
Shen, Liangfang
Wang, Lin
Zou, Guorong
Lin, Xiaoyan
Lin, Shaojun
Li, Minying
Wang, Ying
Xu, Ruilian
Ao, Rui
Wang, Rensheng
Lin, Haifeng
Huang, Shuang
Xu, Tingting
Li, Wenting
Xia, Mengying
Xia, Yu
Wang, Zhongmin
Li, Baiyong
Li, Jingao
Hu, Chaosu
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
[5] An open-label, single-center phase II trial of cadonilimab (an anti-PD-1/CTLA-4 bispecific antibody) in combination with platinum-based dual-drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma
Cao, Fei
Wu, Di
Xu, PengFei
Fang, Qi
Zhao, Zheng
Zhang, Xinrui
Yan, Honghong
Jiang, Ke
Zhou, Jian
Li, Yan
Lu, Li-Xia
Chen, Chunyan
Han, Fei
Li, Zhiming
Liu, Xuekui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic nasopharyngeal carcinoma (R/M NPC)
Wen, L.
Zhang, Z.
Huang, J.
Hong, X.
Wu, B.
Ding, Q.
Peng, G.
Yang, K.
ANNALS OF ONCOLOGY, 2024, 35
[7] Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial
Ren, Chao
Mai, Zong-Jiong
Jin, Ying
He, Ming-Ming
Wang, Zhi-Qiang
Luo, Hui-Yan
Zhang, Dong-Sheng
Wu, Chen-Yi
Wang, Feng
Xu, Rui-Hua
AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2946 - +
[8] Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors
Perez-Santos, Martin
PHARMACEUTICAL PATENT ANALYST, 2020, 9 (05) : 149 - 154
[9] Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
Gao, Xiangyu
Xu, Nong
Li, Ziyu
Shen, Lin
Ji, Ke
Zheng, Zhong
Liu, Dan
Lou, Hanmei
Bai, Li
Liu, Tianshu
Li, Yunxia
Li, Yuzhi
Fan, Qingxia
Feng, Mei
Zhong, Haijun
Huang, Yi
Lou, Ge
Wang, Jing
Lin, Xiaoyan
Chen, Ye
An, Ruifang
Li, Changzheng
Zhou, Qi
Huang, Xin
Guo, Zengqing
Wang, Shubin
Li, Guiling
Fei, Junwei
Zhu, Lijing
Zhu, Hong
Li, Xiumin
Li, Fenghu
Liao, Sihai
Min, Qinghua
Tang, Lei
Shan, Fei
Gong, Jifang
Gao, Yunong
Zhou, Jun
Lu, Zhihao
Li, Xiaofan
Li, Jianjie
Ren, Hui
Liu, Xiaohong
Yang, Hongxia
Li, Wenting
Song, Weifeng
Wang, Zhongmin Maxwell
Li, Baiyong
Xia, Michelle
LANCET ONCOLOGY, 2023, 24 (10): : 1134 - 1146
[10] Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study.
Hu, Xu
Zhao, Fengnian
Chen, Yuntian
Zhao, Junjie
Shi, Yifu
Tang, Yanfeng
Wang, Yongquan
Zhang, Xingming
Liang, Jiayu
Zhao, Jinge
Chen, Junru
Wei, Qiang
Li, Xiang
Liu, Jiyan
Chen, Ni
Shen, Pengfei
Yao, Jin
Sun, Guangxi
Liu, Zhenhua
Zeng, Hao
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 544 - 544

← 1 2 3 4 5 →